Serum Institute of India to Manufacture Oxford Ebola Vaccine — Backed by $8.6 Million CEPI Funding

The same Oxford–Serum Institute alliance that helped defeat COVID-19 is now betting its proven playbook on the Oxford Ebola Vaccine — and CEPI is backing every step.

Sweekriti RajHealth Desk

4 Jun 2026 · 12:41 PM IST5 min read

Serum Institute of India to Manufacture Oxford Ebola Vaccine — Backed by $8.6 Million CEPI Funding

Frequently Asked Questions

What is the ChAdOx1 platform used in the Oxford Ebola vaccine?

The ChAdOx1 platform is a proven vaccine technology developed by the University of Oxford. It is the same platform used to create the famous Oxford-AstraZeneca COVID-19 vaccine. It is now being used to develop the Bundibugyo Ebola vaccine.

Is there any licensed vaccine available for Bundibugyo ebolavirus?

Who are the other vaccine developers working on Bundibugyo ebolavirus?

How fast can Serum Institute of India manufacture vaccines?

When will the Oxford Ebola vaccine be ready for humans?

About the Author

Sweekriti Raj

Health Desk

Dedicated storyteller transforming headlines into meaningful content that educates, engages, and builds trust with readers worldwide.

View Profile